Fallopian tube cancer is rare — accounting for about 2% of gynecologic cancers — but it shares the same biology as high-grade ovarian cancer, and most clinical trials include both. Surgery to remove the uterus, ovaries, and fallopian tubes is typically the first step, followed by platinum and taxane chemotherapy. About 15% of cases are linked to BRCA1 or BRCA2 mutations.
What's actually going on in research
Because fallopian tube cancer shares its biology with ovarian and peritoneal cancer, the research pipeline covers all three. Trials are testing PARP inhibitors as maintenance therapy after chemotherapy, antibody-drug conjugates that target specific proteins on cancer cells, and immunotherapy combinations. Genetic testing for BRCA and other DNA-repair mutations now shapes both treatment decisions and trial eligibility.
PARP inhibitors
Drugs like olaparib, niraparib, and rucaparib block a DNA-repair pathway that cancer cells depend on. Trials have shown they can delay cancer from returning after chemotherapy, with the strongest benefit in people with BRCA mutations.
Antibody-drug conjugates
These drugs attach a chemotherapy agent to an antibody that homes in on cancer cells, delivering treatment more directly and sparing more healthy tissue. Mirvetuximab soravtansine is now approved for folate receptor-positive ovarian and fallopian tube cancer that has returned after treatment.
Immunotherapy combinations
Checkpoint inhibitors are being combined with chemotherapy and targeted drugs to test whether the immune system can be activated to attack remaining cancer cells. Results have been mixed so far, with ongoing trials refining which patients are most likely to respond.
What to know before you search
Eligibility typically depends on cancer stage, prior treatment history, whether cancer has returned, BRCA or other genetic mutation status, and how well the cancer responded to platinum chemotherapy.
What types of trials are currently open
- Maintenance therapy trials — Testing whether a drug taken after chemotherapy can delay cancer from returning. PARP inhibitors are the most-studied option, especially for people with BRCA mutations.
- First-line treatment trials — Testing new combinations given alongside or instead of standard platinum and taxane chemotherapy. Some add a targeted drug or immunotherapy to the standard regimen.
- Recurrent cancer trials — Testing options for cancer that has returned after initial treatment, including antibody-drug conjugates and drugs matched to specific gene mutations.
- BRCA and hereditary cancer trials — Studies specifically for people with BRCA1, BRCA2, or other DNA repair gene mutations — often requiring genetic test results for eligibility.
- Biomarker studies — Collecting tissue, blood, and imaging data to understand why some cancers respond to treatment and others do not.
Recently added Fallopian Tube Cancer trials
Receive engineered immune cells designed to fight ovarian cancer
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in participants with recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer. At screening, each participant's tumor is assessed for expression of Mesothelin (MSLN), Folate Receptor alpha (FRalpha/FOLR1), and MUC16 (CA 125). Participants are assigned to the dual-target CAR-NK product that best matches their tumor antigen profile to reduce the risk of antigen escape.
Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
This study evaluates the safety, tolerability, and preliminary anti-tumor activity of EB-DUALNK, a dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy, in adults with recurrent or refractory epithelial ovarian cancer. Candidates for targeting include GD2, MUC1, PSMA, and mesothelin. After baseline biomarker assessment (tumor antigen expression), the program will select the most suitable dual-target pair for clinical testing. Participants will receive lymphodepleting chemotherapy followed by EB-DUALNK infusion and safety/response follow-up.
Find Fallopian Tube Cancer trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.